Establishment of a human fibroblast cell line producing tumor necrosis factor α (KMST-6/TNF) and growth inhibitory effects of its conditioned medium on malignant cells in culture

In Vitro Cellular and Developmental Biology - Animal

Volumn 34, Issue 6, 1998, Pages 463-467

  Fushimi, Kazuo ^a   Torigoe, Kakuji ^b   Yamauchi, Hiroshi ^b   Furusako, Shouji ^a   Kurimoto, Masashi ^b   Namba, Masayoshi ^a  

^a OKAYAMA UNIVERSITY MEDICAL SCHOOL   (Japan)

^b HAYASHIBARA BIOCHEMICAL LABORATORIES INC   (Japan)

Author keywords

Cancer cells; Gene therapy; Human; TNF

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; GAMMA INTERFERON; TUMOR NECROSIS FACTOR ALPHA;

ARTICLE; CANCER CELL CULTURE; FIBROBLAST; GENE THERAPY; GROWTH INHIBITION; HUMAN; HUMAN CELL;

EID: 0032443525     PISSN: 10712690     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11626-998-0079-9     Document Type: Article

References (23)

1. Abbruzzese, J. L.; Levin, B.; Ajani, J. A., et al. Phase I trial of recombinant human γ-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. Cancer Res. 49:4057-4061; 1989.
2. Bai, L.; Mihara, K.; Kondo, T., et al. Immortalization of normal human fibroblasts by treatment with 4-nitroquinolinel-oxide. Int. J. Cancer 53:451-456; 1993.
3. Budd, G. T.; Green, S.; Baker, L. H., et al. A southwest oncology group phase II trial of recombinant tumor necrosis factor in melastatic breast cancer. Cancer 68:1694-1695; 1991.
4. Carswell, E. A.; Old, L. J.; Kassel, R. L., et al. An endotoxin-induced serum factor that causes necrosis of tumors. Proc. Natl. Acad. Sci. USA 72:3666-3670; 1975.
5. Chouaib, S.; Bertoglio, J.; Blay, J. Y., et al. Generation of lymphokine-activated killer cells: synergy between tumor necrosis factor and interleukin 2. Proc. Natl. Acad. Sci. USA 85:6875-6879; 1988.
6. Creaven, P. J.; Brenner, D. E.; Cowens, J. W., et al. A phase I clinical trial of recombinant human tumor necrosis factor given daily for five days. Cancer Chemother. Pharmacol. 23:186-191; 1989.
7. Eggimann, P.; Chioléro, R.; Chassot, P. G., et al. Systemic and hemodynamic effects of recombinant tumor necrosis factor alpha in isolation perfusion of the limbs. Chest 107:1074-1082; 1995.
8. Fiers, W. Tumor necrosis factor. Characterization at the molecular, cellular and in vivo level. FEBS Lett. 285:199-212; 1991.
9. Fujii, S.; Liu, Y.; Neda, H., et al. Augmented systemic immunity in mice implanted with tumor necrosis factor-α gene-transduced Meth-A cells. Jpn. J. Cancer Res. 85:315-324; 1994.
10. Fukuda, S.; Ando, S.; Sanou, O., et al. Simultaneous production of natural human tumor necrosis factor-α, -β and interferon-α from BALL-1 cells stimulated by HVJ. Lymphokine Res. 7:175-185; 1988.
11. Goossens, V.; Grooten, J.; de Vos, K., et al. Direct evidence for tumor necrosis factor-induced mitochondrial reactive oxygen intermediates and their involvement in cytotoxicity. Proc. Natl. Acad. Sci. USA 92:8115-8119; 1995.
12. Hahne, M.; Jäger, U.; Isenmann, S., et al. Five tumor necrosis factor-inducible cell adhesion mechanisms on the surface of mouse endothelioma cells mediate the binding of leukocytes. J. Cell Biol. 121:655-1561; 1993.
13. Irmler, M.; Thome, M.; Hahne, M., et al. Inhibition of death receptor signals by cellular FLIP. Nature 388:190-195; 1997.
14. 60Co gamma rays and the human c-Ha-ras oncogene. In Vitro Cell. Dev. Biol. 29A:763-767; 1993.
15. Johnston, M. D.; Finter, N. B.; Young, P. A. Dye uptake method for assay of interferon activity. Methods Enzymol. 78:394-399; 1981.
16. Kessler, M.; Höper, J.; Harrison, D. K., et al. Tissue 02 supply under normal and pathological conditions. In: Lübbers, D. W.; Acker, H.; Leniger-Follert, E., et al., ed. Oxygen transport to tissue-V. New York: Plenum; 1981:69-80.
17. Talmage, J. E.; Phillips, H.; Schneider, M., et al. Immunomodulatory properties of recombinant murine and human tumor necrosis factor. Cancer Res. 48:544-550; 1988.
18. Uren, A. G.; Pakusch, M.; Hawkins, C. J., et al. Cloning and expression of apoptosis inhibitory protein homologs that function to inhibit apoptosis and/or bind tumor necrosis factor receptor associated factors. Proc. Nail. Acad. Sci. USA 93:4974-4978; 1996.
19. Van Antwerp, D. J.; Martin, S. J.; Kafri, T., et al. Suppression of TNF-αinduced apoptosis by NF-κB. Science 274:787-789; 1996.
20. Wang, C. Y.; Mayo, M. W.; Baldwin, A. S., Jr. TNF- and cancer therapyinduced apoptosis: potentiation by inhibition of NF-κB. Science 274:781-787; 1996.
21. Wölfel T.; Herr, W.; Coulie, P., et al. Lysis of human pancreatic adenocarcinoma cells by autologous HLA-class I-restricted cytolylic T-lymphocyte (CTL) clones. Int. J. Cancer 51:636-614; 1993.
22. Wong, G. H. W.; Elwell, J. H.; Oberley, L. W., et al. Manganous superoxide dismutase is essential for cellular resistance to cytotoxicity of tumor necrosis factor. Cell 58:923-931; 1989.
23. Yamazaki, S.; Onishi, E.; Enami, K., et al. Proposal of standardized methods and reference for assaying recombinant human tumor necrosis factor. Jpn. J. Med. Sci. Biol. 39:105-118; 1986.